Pembrolizumab Approved for Classical Hodgkin Lymphoma

PembrolizumabThe FDA has now expanded the approved indications for pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme) to include both adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL, or cHL that has relapsed after two or more lines of therapy. The approval was based on efficacy data from the open-label phase 3 KEYNOTE-204 trial (NCT02684292), for which 304 adult patients with cHL previously treated with at least one multiagen...
Continue reading

Pembrolizumab Approved: Solid Tumors With High Tumor Mutational Burden

The FDA granted accelerated approval to pembrolizumab (Keytruda®, Merck) for adults and children with previously treated unresectable or metastatic tumor mutational burden (TMB)–high solid tumors, defined as tumors with at least 10 mutations per megabase, who have no satisfactory alternative treatment option. The FDA also approved the FoundationOne® CDx assay (Foundation Medicine) as the companion diagnostic used to determine treatment eligibility. The approval was based on data from a prospecti...
Continue reading

Has Life Expectancy for Adult Survivors of Childhood Cancer Improved?

Scientists recently discovered that improved cancer treatment approaches over time correlate with higher life expectancy in adult survivors of childhood cancer. As cancer treatment evolves to be more effective, more patients are surviving, with some even living long lives disease free. In order to determine if life expectancy also rises with evolving treatment, the investigators examined data derived from the Childhood Cancer Survivor Study, which included data on 5-year survivors of childhood c...
Continue reading

In High-Risk Neuroblastoma, Tandem Transplant Is Superior

A randomized clinical trial reports that in patients with neuroblastoma, tandem autologous stem cell transplant improves outcomes compared with single transplant. Neuroblastoma, a malignancy of the developing sympathetic nervous system, is responsible for around 10% to 12% of childhood cancer deaths. For the 43% of patients who present with high-risk disease, which involves either widespread metastasis in patients over the age of 18 months and/or amplification of the MYCN oncogene, the standard ...
Continue reading

Analysis Reveals Substantial Childhood Cancer Burden

As technology and health care progress, the rate of children who survive five years after being diagnosed with cancer is 80%; however, this rate only applies to children who live in high-income countries (HICs). Those children that live in low-income and middle-income countries (LMICs) make up more than 90% of children who are at risk of developing cancer, and, unfortunately, children who live in LMICs lack the resources necessary to combat childhood cancer compared with children who live in HIC...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.